Vistagen Therapeutics, Inc. (VTGN) Return on equity 2017–2026
Vistagen Therapeutics, Inc. (VTGN) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-196.2%FY2026 · since FY2017: -1665.4% → -196.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -196.2% | -123.1 pp |
| FY2025 | -73.0% | -47.4 pp |
| FY2024 | -25.7% | +464.8 pp |
| FY2023 | -490.5% | -416.7 pp |
| FY2022 | -73.8% | -54.3 pp |
| FY2021 | -19.5% | — |
| FY2018 | -207.4% | +1458.0 pp |
| FY2017 | -1665.4% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice